SLC7A11 and neoplasm: The loss of tumor suppressor genes, mutations in oncogenes, or the overexpression of pro-tumor proteins elevates levels of SLC7A11 in cancer, resulting in the inhibition of ferroptosis and enhanced tumor progression [32,33,34,35].